促红细胞生成素治疗冠心病慢性心力衰竭合并贫血的临床观察

目的探讨促红细胞生成素（EPO）治疗冠心病慢性心力衰竭（CHF）合并贫血的临床效果。方法将138例冠心病CHF合并贫血的患者随机分为治疗组（A组）和对照组（B组）。B组患者给予常规药物治疗，A组患者在常规药物治疗的基础上加用EPO，使其血红蛋白浓度≥110g／L。随访6个月，观察两组患者的治疗效果。结果A组患者治疗后的总有效率明显优于B组（P〈0．05）。两组患者治疗后心功能分级、左室射血分数、左室舒张末内径、6min步行距离及BNP水平等均改善（P〈0．05）。与B组比较，A组患者上述各指标改善更显著（P〈0．05）。结论EPO可减轻冠心病CHF合并贫血患者的临床症状，提高疗效。

Clinical observation of erythropoietin in the treatment of patients with anemia combined chronic heart failure resulting from coronary heart disease

Objective To observe the clinical efficacy of erythropoietin in the treatment of patients with anemia combined chronic heart failure resulting from coronary heart disease. Methods 138 patients with combined chronic heart failure resulting from coronary heart disease and anemia were selected and randomly divided into treatment group （group A） and control group （group B ）, with 69 patients in each group. The patients in group B were treated with conventional therapy. The patients in group A were treated with erythropoietin besides eanvention- al therapy, the hemoglobin concentration of which increased to or above 110 g/L. All the patients were followed up for 6 months. The clinical efficacy of both groups were observed. Results The total effective rate of group A was significantly higher than that of the group B （P〈0.05）. After treatment, the indicators such as hemoglobin concentration, heart function classification, left ventricular ejection fraction（LVEF）, left ventricular end diastolic diame- ter （LVEDD）, walking distance for 6 minutes, and BNP level were all significantly improved in both groups （P〈 0.05 ）. While the improvement in group A was much more significant than that of group B（P〈0.05 ）. Conclusion Erythropoietin can reduce the clinical symptoms of patients with combined chronic heart failure resulting from coronary heart disease and anemia, and improve the clinical efficacy.